Search Results - "Bourlon, María"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer by Chávarri-Guerra, Yanin, Bourlon, María T., Rodríguez-Olivares, José L., Orozco, Luis, Bazua, Deborah, Rodríguez-Faure, Andrés, Alcalde-Castro, Mirza J., Castro, Elena, Castillo, Danielle, Herzog, Josef, Weitzel, Jeffrey

    Published in Clinical genitourinary cancer (01-10-2023)
    “…Early identification of germline mutation carriers may be relevant for the optimal management of prostate cancer and to inform cancer risk in relatives…”
    Get full text
    Journal Article
  5. 5

    CHALLENGES OF TREATING YOUNG WOMEN WITH CANCER IN THE ERA OF NEW ONCOLOGIC TREATMENTS by Bourlon, María T, Barragan-Carrillo, Regina, Mesa-Chavez, Fernanda, Villarreal-Garza, Cynthia

    Published in Revista de investigacion clinica (2021)
    “…Young women with cancer comprise a special population of patients who experience cancer and oncologic care in a unique way. Recent progress in diagnostic and…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors by Rodríguez-Olivares, José Luis, González-Sánchez, Héctor Raúl, Beas-Lozano, Evelyn Lilian, Arteaga-Vázquez, Jazmin, Elaine T Lam Md, Bourlon, María T

    Published in Oncology (Williston Park, N.Y.) (01-10-2024)
    “…The Case A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest…”
    Get more information
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent by Gonzalez-Ochoa, Eduardo, Verduzco-Aguirre, Haydee, Crawford, E David, Bourlon, María T

    Published in Oncology (Williston Park, N.Y.) (10-04-2020)
    “…KEY POINTS • The prognosis for patients with mCRPC has improved over the last few years due to the introduction of novel agents. • The optimal sequence of…”
    Get more information
    Journal Article
  12. 12

    Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population by Morales-Chacón, Katherinee, Bourlon, Christianne, Acosta-Medina, Aldo A., Bourlon, María T., Aguayo, Alvaro, Tuna-Aguilar, Elena

    Published in Clinical lymphoma, myeloma and leukemia (01-06-2019)
    “…Additional cytogenetic abnormalities (ACA) in patients with chronic myeloid leukemia (CML) are related to an increased risk of treatment failure, leukemic…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Maintenance immunotherapy in advanced urothelial cancer by María T. Bourlon, Nora Sobrevilla-Moreno

    Published in Gaceta Mexicana de oncología (01-07-2022)
    “…Advanced urothelial carcinoma usually responds to platinum-based chemotherapy (CT), although overall survival (OS) and progression-free survival are typically…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19

    Organization of a Third-level Care Hospital in Mexico City during the 2009 Influenza Epidemic by Bourlon, María T, Macias, Alejandro E, de la Torre, Alethse, Gulias-Herrero, Alfonso, Leal, Patricia E, Domínguez-Cherit, Guillermo, Huertas, Martha, Ruiz-Palacios, Guillermo M

    Published in Archives of medical research (01-11-2009)
    “…An outbreak caused by the novel swine-origin influenza A (H1N1) virus was identified in Mexico in late March 2009. The objective of this report is to describe…”
    Get full text
    Journal Article
  20. 20

    The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials by Carretero-González, Alberto, Lora, David, Martín Sobrino, Isabel, Sáez Sanz, Irene, Bourlon, María T, Anido Herranz, Urbano, Martínez Chanzá, Nieves, Castellano, Daniel, de Velasco, Guillermo

    Published in Cancers (17-07-2020)
    “…Immune checkpoint inhibitors (ICIs) are soluble antibodies that have dramatically changed the outcomes including overall survival in a subset of kidney tumors,…”
    Get full text
    Journal Article